We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials

News   Oct 20, 2009

 
Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials
 
 
 

RELATED ARTICLES

Blood Test Could Reveal High Risk Heart Patients in Need of Treatment

News

Without occasionally looking under the hood, it’s difficult to predict whether expensive car repairs lie ahead. In a similar way, preventive cardiologists are looking for ways to detect early stage heart disease in people who aren’t currently in treatment.

READ MORE

GW Pharmaceuticals Receives Positive NICE Recommendation for EPIDYOLEX (Cannabidiol)

News

GW Pharmaceuticals plc announces that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England.

READ MORE

Novel “Fizzy” Patch Could Provide Contraceptive Protection to Women

News

Scientists have created a reversible contraceptive microneedle patch that is able to slowly release the hormone levonorgestrel, through the skin. The study was published November 6, 2019, in Science Advances.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE